Why the study?
Do lipoprotein lipase mutations (Gly188Glu, Asp9Asn, Asn291Ser, Ser447Ter) alter the lipoprotein profile and risk of ischemic heart disease compared to noncarriers?
Do lipoprotein lipase mutations (Gly188Glu, Asp9Asn, Asn291Ser, Ser447Ter) alter the lipoprotein profile and risk of ischemic heart disease compared to noncarriers?
Specific lipoprotein lipase mutations differentially affect lipoprotein profiles and the subsequent risk of ischemic heart disease, with some being atherogenic and others protective.
LPL variant status may refine IHD risk assessment in dyslipidemia; confirms mutation-specific atherogenic versus protective effects.
These meta-analyses suggest that compared with noncarriers, carriers of the Gly188Glu, Asp9Asn, and Asn291Ser substitutions have an atherogenic lipoprotein profile, whereas carriers of the Ser447Ter substitution have a protective lipoprotein profile. Accordingly, risk of ischemic heart disease in heterozygous carriers is increased for Gly188Glu carriers; at most, the increase is borderline for Asp9Asn and Asn291Ser carriers; and risk is possibly decreased for Ser447Ter carriers.
No takes yet. Share an insight, caveat, or question.
Wittrup et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: